DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Canakinumab
Canakinumab
Old and New Challenges in Uveitis Associated with Behçet's Disease
Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
Ilaris Canakinumab for Systemic Juvenile Idiopathic Arthritis SJIA
Inflammatory Conditions – Kevzara™ (Sarilumab for Subcutaneous Injection)
761037Orig1s000
Cytokine & CAM Antagonists
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Immunomodulators
Soluble Ligands As Drug Targets
Therapeutic Class Overview Immunomodulators
ILARIS (I-LAHR-Us) (Canakinumab) Injection for Subcutaneous Use
Secukinumab (COSENTYX) Monograph
Canakinumab (Ilaris) Effective 07/01/2021
INN Working Document 05.179 Update 2011
Nanoparticles in Neutrophil Clothing
IL-23 Inhibitors
ILARIS (Canakinumab) During an Active Infection Requiring Medical Intervention
Ilaris® (Canakinumab)
Top View
Inflammatory Conditions – Ilaris® (Canakinumab for Subcutaneous Injection)
Drug Class Review Targeted Immune Modulators
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Ilaris, INN-Canakinumab
(INN) for Biological and Biotechnological Substances
Long-Term Safety and Effectiveness of Canakinumab Therapy
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Struggles with Clinical Translation of Immune Intervention Trials Diabetes Care 2014;37:1173–1175 | DOI: 10.2337/Dc13-2878 Jay S
Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderate-To-Severe Plaque Psoriasis
The Way Forward for the Refractory Asthmatic
Effect of Disease Modifying Anti-Rheumatic Drugs On
Anti-IL-1Β (Canakinumab), Human Igg1 Antibody
Utah Medicaid Pharmacy and Therapeutics Committee Drug
ILARIS® (Canakinumab)
Prediction of Clearance of Monoclonal and Polyclonal Antibodies and Non-Antibody Proteins in Children: Application of Allometric Scaling
Ilaris ® (Canakinumab) Medical Policy (PDF)
PATIENT FACT SHEET (Ilaris)
Ixekizumab Injection, Subcutaneous
Ilaris (Canakinumab) Policy Number: C2435-A
Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases
Novartis R&D
New Drug Evaluation Monograph Template
RCR15: Canakinumab
COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases
Appendix A: Dosing Regimens Modelled
Policy: 201703 Initial Effective Date: 02/14/2017 HCPCS J0638 Code(S): Annual Review Date: 10/15/2020
Drug Effectiveness Review Project Summary Report – Biologics (Targeted Immune Modulators)
FDA Approved Indications1-3
Understanding the Monoclonal Antibody Disposition After Subcutaneous Administration Using a Minimal Physiologically Based Pharmacokinetic Model
Ilaris (Canakinumab) Prior Authorization of Benefits Form
Susceptibility and Severity of COVID-19 in Patients Treated With
Blockage of Interleukin-1Β with Canakinumab in Patients with Covid
Study Protocol and Results
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Simponi® Non-Preferred: N/A
Experience with Etanercept, Tocilizumab and Interleukin-1
(INN) for Biological and Biotechnological Substances
Atopic Dermatitis Agents
Therapeutic Class Overview Immunomodulators
Tocilizumab (Actemra) Shortage: Patient Management
Assessment of the Evolution of Cancer Treatment Therapies
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Ilaris® (Canakinumab)
Specialty Pipeline Update
Canakinumab (Ilaris®) Is Considered Medically Necessary When ANY of the Following Criteria Are Met
Cytokine and CAM Antagonists
Ocular Side Effects of Antirheumatic Medications: a Qualitative Review
Risk of Infection Associated with Biological Agents Used for Autoimmune Inflammatory Diseases
Sarilumab for the Treatment of Covid-19
RA, IBD, Psoriasis